Research on GLP-1 therapy shows that approximately 6070% of patients report significant improvement in bloating by the end of their second month of treatment, even without making additional dietary changes
Youve probably heard of gastrointestinal issues, which can be common among weight loss patients using these medications
Clinical trials testing GLP-1 receptor agonists in patients with AD or PD have been conducted and have shown first successes, serving as proof of concept that activating GLP-1 receptor is a sensible strategy to treat AD/PD
The compounds discussed are for research use only and are not for human consumption
There is no official indication from Novo or Eli Lilly on a fresh round of price cuts, acknowledged the Mumbai-based diabetologist, but said that "Novo will bite the bullet eventually." Meanwhile, he plans to wait for more evidence on the effectiveness and availability of the new generics before switching his patients from Novo's and Lilly's GLP-1 drugs
American Society for Reproductive Medicine (ASRM) is the professional society made up of OBGYNs with advanced training and focus on infertility